4 assets in Lung Superior Sulcus Carcinoma

Therapeutic assets addressing Lung Superior Sulcus Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Lung Superior Sulcus Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Carboplatin Lung Superior Sulcus Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Cis-Diamminedichloroplatinum Ii Lung Superior Sulcus Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Etoposide Lung Superior Sulcus Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)